-
CIRC’s Subsidiary HTA Co., Ltd. Secures NMPA Approval for Sodium Fluoride [18F] for Bone Imaging
•
China Isotope & Radiation Corporation’s (CIRC) subsidiary, HTA Co., Ltd. (HKG: 1763), has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its sodium fluoride [18F]. This product is primarily utilized in positron emission tomography (PET) to identify areas of altered osteogenic activity in…
-
China Isotope & Radiation Corporation Secures NMPA License for Innovative Radiotherapy System
•
China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced that it has received a medical device license from the National Medical Products Administration (NMPA) for its innovative gamma beam stereotactic radiotherapy system. This new system represents a significant advancement in the field of radiation therapy. The product streamlines the…
-
China Isotope & Radiation Corporation to Establish Cancer Treatment Center in Nigeria
•
China Isotope & Radiation Corporation (CIRC; HKG: 1763), a leading provider of medical equipment and services, has announced plans to supply a substantial amount of medical equipment to Nigeria. The company is tasked with establishing a new cancer diagnosis and treatment center as part of an extensive program. This initiative…
-
CIRC Unveils FuZhi 1.0 Smart Nuclear Medicine System at Chinese Medical Association Meeting
•
China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced the launch of its innovative FuZhi 1.0 smart nuclear medicine system at the 2023 annual meeting of the Nuclear Medicine Branch of the Chinese Medical Association. This comprehensive system, which includes modules for smart patient care, smart nuclear drug management,…
